Cargando…

Corrigendum to ‘Exosomal miRNA confers chemo resistance via targeting Cav1/p-gp/M2-type macrophage axis in ovarian cancer’ [EBioMedicine 38 (2018) 100–112]

Detalles Bibliográficos
Autores principales:	Kanlikilicer, Pinar, Bayraktar, Recep, Denizli, Merve, Rashed, Mohammed H., Ivan, Cristina, Aslan, Burcu, Mitra, Rahul, Karagoz, Kubra, Bayraktar, Emine, Zhang, Xinna, Rodriguez-Aguayo, Cristian, El-Arabey, Amr Ahmed, Kahraman, Nermin, Baydogan, Seyda, Ozkayar, Ozgur, Gatza, Michael L., Ozpolat, Bulent, Calin, George A., Sood, Anil K., Lopez-Berestein, Gabriel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2020
Materias:	Corrigendum
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6974767/ https://www.ncbi.nlm.nih.gov/pubmed/31972470 http://dx.doi.org/10.1016/j.ebiom.2020.102630

Ejemplares similares

Exosomal miRNA confers chemo resistance via targeting Cav1/p-gp/M2-type macrophage axis in ovarian cancer
por: Kanlikilicer, Pinar, et al.
Publicado: (2018)

MicroRNA 603 acts as a tumor suppressor and inhibits triple-negative breast cancer tumorigenesis by targeting elongation factor 2 kinase
por: Bayraktar, Recep, et al.
Publicado: (2016)

Correction: MicroRNA 603 acts as a tumor suppressor and inhibits triple-negative breast cancer tumorigenesis by targeting elongation factor 2 kinase
por: Bayraktar, Recep, et al.
Publicado: (2023)

The Modulatory Role of MicroRNA-873 in the Progression of KRAS-Driven Cancers
por: Mokhlis, Hamada A., et al.
Publicado: (2018)

EBioMedicine: Translating Science to Improve Health
por: EBioMedicine
Publicado: (2018)

Happy 5th birthday, EBioMedicine!
Publicado: (2019)

EBioMedicine: Bridging Two Cultures to Improve Health
Publicado: (2014)

Corrigendum to “PTGER3 induces ovary tumorigenesis and confers resistance to cisplatin therapy through up-regulation Ras-MAPK/Erk-ETS1-ELK1/CFTR1 axis” [EBioMedicine 40 (2019) 290-304]
por: Rodriguez-Aguayo, Cristian, et al.
Publicado: (2022)

Exosomal miR-940 maintains SRC-mediated oncogenic activity in cancer cells: a possible role for exosomal disposal of tumor suppressor miRNAs
por: Rashed, Mohammed H, et al.
Publicado: (2017)

ncRNA therapy with miRNA-22-3p suppresses the growth of triple-negative breast cancer
por: Gorur, Aysegul, et al.
Publicado: (2021)

The duplicitous nature of ACE2 in COVID-19 disease EBioMedicine (invited commentary)
por: Heyman, Samuel N., et al.
Publicado: (2021)

Targeting miRNAs and Other Non-Coding RNAs as a Therapeutic Approach: An Update
por: Bayraktar, Emine, et al.
Publicado: (2023)

Corrigendum to “Syk and ye shall find” [EBioMedicine 2 (11) (2015) 190-1591]
por: Wolozin, Benjamin, et al.
Publicado: (2016)

Corrigendum to “Cholangiopathies – Towards a molecular understanding” [EBioMedicine 35 (2018) 381–393]
por: Tam, Paul K.H., et al.
Publicado: (2018)

Corrigendum to ‘PRAS40 hyperexpression promotes hepatocarcinogenesis’ [EBioMedicine 51 (2020) 102,604]
por: Qi, Zhaolai, et al.
Publicado: (2020)

Therapeutic Targeting of AXL Receptor Tyrosine Kinase Inhibits Tumor Growth and Intraperitoneal Metastasis in Ovarian Cancer Models
por: Kanlikilicer, Pinar, et al.
Publicado: (2017)

Corrigendum to “Intergenerational Transmission of Enhanced Seizure Susceptibility after Febrile Seizures” (EBioMedicine 17 (2017) 206–215)
por: Wu, Dengchang, et al.
Publicado: (2017)

Corrigendum to “Allergic Conjunctivitis-induced Retinal Inflammation Promotes Myopia Progression” [EBioMedicine 28 (2018) 274–286]
por: Wei, Chang-Ching, et al.
Publicado: (2019)

Corrigendum to ‘Osteoblastic PLEKHO1 contributes to joint inflammation in rheumatoid arthritis’ [EBioMedicine 41 (2019) 538–555]
por: He, Xiaojuan, et al.
Publicado: (2020)

Corrigendum to “Linezolid for Treating Tuberculosis: A Delicate Balancing Act” [EBioMedicine 2 (11) (November 2015) 1568–1569]
Publicado: (2015)

Erratum to “Efficacy of Adjunctive Tofacitinib Therapy in Mouse Models of Tuberculosis” [EBioMedicine 2 (8), August 2015, 868–873]
por: Maiga, Mamoudou, et al.
Publicado: (2015)

Corrigendum to “Lifetime risk of autosomal recessive mitochondrial disorders calculated from genetic databases” [EBioMedicine 54 (2020) 102730]
por: Tan, Jing, et al.
Publicado: (2020)

Corrigendum to ‘Combined gene essentiality scoring improves the prediction of cancer dependency maps’ [EBioMedicine 50 (2019) 66–79]
por: Wang, Wenyu, et al.
Publicado: (2020)

Corrigendum to “Serotonin Activates Bacterial Quorum Sensing and Enhances the Virulence of Pseudomonas aeruginosa in the Host” [EBioMedicine 9 (2016) 161–169]
por: Knecht, Leslie D., et al.
Publicado: (2017)

Corrigendum to “TRPA1 inhibition ameliorates pressure overload-induced cardiac hypertrophy and fibrosis in mice” [EBioMedicine (2018) 54–62]
por: Wang, Zhen, et al.
Publicado: (2018)

Corrigendum to “Dynamic assessment of tau immunotherapies in the brains of live animals by two-photon imaging” EBioMedicine 35 (2018) 270–278
por: Wu, Qian, et al.
Publicado: (2018)

Corrigendum to ‘Fibroblast growth factor 19 modulates intestinal microbiota and inflammation in presence of farnesoid x receptor’: [EBioMedicine 54 (2020) 102719]
por: Gadaleta, Raffaella Maria, et al.
Publicado: (2020)

Corrigendum to ‘single-cell transcriptomics of blood reveals a natural killer cell subset depletion in tuberculosis’ [EBioMedicine 53 (2020) 102686]
por: Cai, Yi, et al.
Publicado: (2022)

Corrigendum to “Endoplasmic reticulum stress is activated in post-ischemic kidneys to promote chronic kidney disease” [EBioMedicine 37 (2018) 269–280]
por: Shu, Shaoqun, et al.
Publicado: (2021)

Corrigendum to “TNF-α is a potential therapeutic target to overcome sorafenib resistance in hepatocellular carcinoma” [EBioMedicine 40 (2019) 446–456]
por: Tan, Wenliang, et al.
Publicado: (2022)

Corrigendum to “poFUT1 promotes endometrial decidualization by enhancing the O-fucosylation of Notch1” [EBioMedicine 44 (2019) 563–573]
por: Yang, Yu, et al.
Publicado: (2023)

Corrigendum to: “Small Molecule Inhibitor of CBFβ-RUNX Binding for RUNX Transcription Factor Driven Cancers” [EBioMedicine 8 (2016) 117–131]
por: Illendula, Anuradha, et al.
Publicado: (2017)

Corrigendum to “Sec23a mediates miR-200c augmented oligometastatic to polymetastatic progression” [EBioMedicine 37 (2018) 47–55]
por: Sun, Zhiwei, et al.
Publicado: (2021)

Corrigendum to ‘Silencing KIF18B enhances radiosensitivity: Identification of a promising therapeutic target in sarcoma’ [EBioMedicine 61 (2020) 103,056]
por: Liu, Wensi, et al.
Publicado: (2021)

Erratum to “Tumor cells hijack enteric glia to activate colon cancer stem cells and stimulate tumorigenesis” [EBioMedicine 49 (2019) 172–188]
por: Valès, Simon, et al.
Publicado: (2023)

Erratum to “Mechanistic Studies of the Negative Epistatic Malaria-protective Interaction Between Sickle Cell Trait and α(+)thalassemia” [EBioMedicine 1 (2014) 29–36]
por: Opi, D. Herbert, et al.
Publicado: (2015)

Corrigendum to “APPBP2 enhances non-small cell lung cancer proliferation and invasiveness through regulating PPM1D and SPOP” [EBioMedicine (2019)]
por: Gong, Huiyuan, et al.
Publicado: (2019)

Corrigendum to ‘Gut microbiota from colorectal cancer patients enhances the progression of intestinal adenoma in Apc(min)(/+) mice’ [EBioMedicine 48 (2019) 301–315]
por: Li, Lu, et al.
Publicado: (2020)

Corrigendum to ‘Silencing of circular RNA HIPK2 in neural stem cells enhances functional recovery following ischaemic stroke’ [EBioMedicine 52 (2020) 102660]
por: Wang, Guangtian, et al.
Publicado: (2020)

Retraction notice to ‘The antineoplastic drug metformin downregulates YAP by interfering with IRF-1 binding to the YAP promoter in NSCLC’ [EBioMedicine 37 (2018) 188–204]
por: Jin, Dan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_a8i6d25fmqh6f7mi3kvkpb83mb